Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02609737 · ClinicalTrials.gov registry record · NA
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02609737: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02609737 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02609737, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).
Interventions
- DEVICE PET/CT Imaging
- RADIATION 68Ga-DOTA-JR11
- RADIATION 177Lu-DOTA-JR11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-11-13 |
| Est. Completion | 2020-12-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02609737
The ClinicalTrials.gov registry entry for NCT02609737 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PET/CT Imaging is the first listed.
NCT02609737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02609737 about?
NCT02609737 is a clinical study titled "Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors". This study has 3 steps and not everyone will have all 3 steps done. The overall goals are to see if a new experimental drug is safe to image (step 1) and treat neuroendocrine tumors (step 2 and 3).
What is the current status of trial NCT02609737?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-11-13. Estimated completion is 2020-12-10.
What interventions are being tested in trial NCT02609737?
The interventions under investigation include: PET/CT Imaging (DEVICE), 68Ga-DOTA-JR11 (RADIATION), 177Lu-DOTA-JR11 (RADIATION).
Who is sponsoring clinical trial NCT02609737?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.